These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29725632)

  • 21. Tissue expression of tubular injury markers is associated with renal function decline in diabetic nephropathy.
    Hwang S; Park J; Kim J; Jang HR; Kwon GY; Huh W; Kim YG; Kim DJ; Oh HY; Lee JE
    J Diabetes Complications; 2017 Dec; 31(12):1704-1709. PubMed ID: 29037450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations of urinary levels of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) with kidney function decline in the Multi-Ethnic Study of Atherosclerosis (MESA).
    Peralta CA; Katz R; Bonventre JV; Sabbisetti V; Siscovick D; Sarnak M; Shlipak MG
    Am J Kidney Dis; 2012 Dec; 60(6):904-11. PubMed ID: 22749388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
    Nakajima A; Lu Y; Kawano H; Horie S; Muto S
    Clin Exp Nephrol; 2015 Dec; 19(6):1199-205. PubMed ID: 25715868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
    Kline TL; Korfiatis P; Edwards ME; Bae KT; Yu A; Chapman AB; Mrug M; Grantham JJ; Landsittel D; Bennett WM; King BF; Harris PC; Torres VE; Erickson BJ;
    Kidney Int; 2017 Nov; 92(5):1206-1216. PubMed ID: 28532709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum bicarbonate is associated with kidney outcomes in autosomal dominant polycystic kidney disease.
    Blijdorp CJ; Severs D; Musterd-Bhaggoe UM; Gansevoort RT; Zietse R; Hoorn EJ;
    Nephrol Dial Transplant; 2021 Dec; 36(12):2248-2255. PubMed ID: 33377160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Baseline Urinary Metabolic Biomarkers with ADPKD Severity in TAME-PKD Clinical Trial Participants.
    Hallows KR; Althouse AD; Li H; Saitta B; Abebe KZ; Bae KT; Miskulin DC; Perrone RD; Seliger SL; Watnick TJ
    Kidney360; 2021 May; 2(5):795-808. PubMed ID: 34316721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The utility of serum neutrophil gelatinase-associated lipocalin level on predicting autosomal dominant polycystic kidney disease progression.
    Uysal C; Koyuncu S; Ipekten F; Karakukcu C; Kocyigit I
    Ther Apher Dial; 2024 Oct; 28(5):760-768. PubMed ID: 38773764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
    Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C;
    J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of urine biomarkers of kidney injury in polycystic kidney disease.
    Parikh CR; Dahl NK; Chapman AB; Bost JE; Edelstein CL; Comer DM; Zeltner R; Tian X; Grantham JJ; Somlo S
    Kidney Int; 2012 Apr; 81(8):784-90. PubMed ID: 22258321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy.
    Peters HP; Waanders F; Meijer E; van den Brand J; Steenbergen EJ; van Goor H; Wetzels JF
    Nephrol Dial Transplant; 2011 Nov; 26(11):3581-8. PubMed ID: 21467131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glomerular and tubular damage markers are elevated in patients with diabetes.
    Nauta FL; Boertien WE; Bakker SJ; van Goor H; van Oeveren W; de Jong PE; Bilo H; Gansevoort RT
    Diabetes Care; 2011 Apr; 34(4):975-81. PubMed ID: 21307379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of Urinary Neutrophil Gelatinase-Associated Lipocalin for Predicting the Severity of Renal Functions in Patients With Autosomal-Dominant Polycystic Kidney Disease.
    Vareesangthip K; Vareesangthip K; Limwongse C; Reesukumal K
    Transplant Proc; 2017 Jun; 49(5):950-954. PubMed ID: 28583565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
    Miskulin DC; Abebe KZ; Chapman AB; Perrone RD; Steinman TI; Torres VE; Bae KT; Braun W; Winklhofer FT; Hogan MC; Rahbari-Oskoui F; Moore CG; Flessner MF; Schrier RW;
    Am J Kidney Dis; 2014 Feb; 63(2):214-26. PubMed ID: 24183837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study.
    Brankovic M; Akkerhuis KM; van Boven N; Anroedh S; Constantinescu A; Caliskan K; Manintveld O; Cornel JH; Baart S; Rizopoulos D; Hillege H; Boersma E; Umans V; Kardys I
    Kidney Int; 2018 Apr; 93(4):952-960. PubMed ID: 29191357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased Body Fat and Organic Acid Anions Production Are Associated with Larger Kidney Size in ADPKD.
    Dos Santos Dutra A; Rodrigues FG; da Rocha DR; Vendramini LC; de Matos ACC; Heilberg IP
    Medicina (Kaunas); 2022 Jan; 58(2):. PubMed ID: 35208476
    [No Abstract]   [Full Text] [Related]  

  • 37. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study.
    Fu WJ; Xiong SL; Fang YG; Wen S; Chen ML; Deng RT; Zheng L; Wang SB; Pen LF; Wang Q
    Endocrine; 2012 Feb; 41(1):82-8. PubMed ID: 21779943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of urinary kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and N-acetyl-β-D-glucosaminidase to predict chronic kidney disease progression and adverse outcomes.
    Lobato GR; Lobato MR; Thomé FS; Veronese FV
    Braz J Med Biol Res; 2017 Mar; 50(5):e6106. PubMed ID: 28380198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.
    Higashihara E; Yamamoto K; Kaname S; Okegawa T; Tanbo M; Yamaguchi T; Shigemori K; Miyazaki I; Yokoyama K; Nutahara K
    Clin Exp Nephrol; 2019 Jan; 23(1):100-111. PubMed ID: 30097754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting autosomal dominant polycystic kidney disease progression: review of promising Serum and urine biomarkers.
    Sorić Hosman I; Cvitković Roić A; Fištrek Prlić M; Vuković Brinar I; Lamot L
    Front Pediatr; 2023; 11():1274435. PubMed ID: 38027263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.